Catriona Yale - 04 Nov 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
04 Nov 2025
Transactions value $
$199,983
Form type
4
Filing time
06 Nov 2025, 07:00:04 UTC
Previous filing
12 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yale Catriona Chief Development Officer 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young, Attorney-in-Fact 06 Nov 2025 0001779308

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $100K +3.53K +5.3% $28.35 70.1K 04 Nov 2025 Direct
transaction AKRO Common Stock Options Exercise $100K +4.74K +6.76% $21.10 74.8K 04 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -3.53K -100% $0.00 0 04 Nov 2025 Common Stock 3.53K $28.35 Direct F2
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -4.74K -100% $0.00 0 04 Nov 2025 Common Stock 4.74K $21.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported amount has been adjusted to correct for an overstatement in the Reporting Person's previously reported common stock ownership.
F2 The options are vested and currently exercisable.